SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is attracting significant market attention and community speculation following reports of unsolicited takeover interest from rivals, particularly after its stock's recent slump and ahead of a leadership change. Discussion centers on potential acquisition prices and the company's perceived undervaluation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as recent layoffs and a persistent decline to new all-time lows intensify bearish sentiment with its upcoming Q4 earnings report in focus, triggering widespread calls to fire management and heightening fears of further dilution among the community.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is experiencing heightened trading activity following the FDA approval of its BYSANTI drug for bipolar I disorder and schizophrenia, which notably secured New Chemical Entity status and patent protection until 2044. The community is buzzing with discussions about the stock's significant undervaluation, pointing to its strengthened pipeline and past rejected buyout offers, fueling expectations for a substantial re-rating and potential M&A interest from larger pharmaceutical companies.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending amid an industry-wide selloff in cybersecurity stocks, driven by investor concerns following Anthropic's new "Claude Code Security" tool. However, many in the community and analysts argue this is an overreaction, asserting that AI will enhance, not replace, the critical enterprise security solutions provided by companies like CrowdStrike.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is surging following robust Q4 revenue growth driven by its ANKTIVA immunotherapy, fueling widespread community discussion about a potential short squeeze and significant global expansion for its cancer treatments.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending due to a "SaaS-pocalypse" narrative, as fears that Anthropic's Claude AI tools will disrupt enterprise software are fueling aggressive selling. The community is debating whether this downturn is an overblown panic or a fundamental shift, with many calling current valuations irrational and the sector extremely oversold amidst record volume.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point due to a prominent lawsuit alleging political debanking, alongside recent regulatory fines that fuel broader community discussions around the financial sector's stability and market integrity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors and the community react to former President Trump's re-imposition of higher tariffs following a Supreme Court decision, fueling debate over economic stability and market impact.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending due to heightened anticipation ahead of its upcoming earnings report, sparking intense community debate over its valuation compared to insurtech peers like Lemonade. Many traders are speculating on a significant post-earnings move, driven by rumored strategic partnerships or potential buyouts, while others attribute recent price weakness to aggressive shorting and market manipulation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recently published long-term data confirming Briumvi's best-in-class efficacy and safety, alongside a high-profile MS awareness campaign featuring Christina Applegate. Despite these strong fundamentals and anticipated positive Q4 earnings, many express frustration over the stagnant stock price, fueling calls for a buyout to unlock shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from...

United Therapeutics (NASDAQ:UTHR) EVP Sells $3,953,622.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average...

Vanguard Group Inc. Lowers Position in United Therapeutics Corporation $UTHR

Vanguard Group Inc. decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 0.7% during the third quarter, according to its most recent filing with the SEC...

Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold...

Skandinaviska Enskilda Banken AB publ Lowers Stock Holdings in United Therapeutics Corporation $UTHR

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 78.9% during the third quarter, according to the company in its...

United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

8,211 Shares in United Therapeutics Corporation $UTHR Bought by First National Bank of Omaha

First National Bank of Omaha bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the...

USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates

USANA Health (USNA) delivered earnings and revenue surprises of +46.34% and +0.11%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Tobam Buys 4,953 Shares of United Therapeutics Corporation $UTHR

Tobam raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 183.9% during the third quarter, according to the company in its most recent Form 13F filing with the...

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Current Price	$470.09
Prev Close	$473.42
Open	$472.45
Dividend Yield	0.00%
50-Day Moving Average	$485.36
Beta	0.43
Avg. Volume	353,460.35
PE Ratio	17.94

52-Week High	$519.99
52-Week Low	$266.98
Market Capitalization	$32.99B
EPS (Annual)	$24.64
Price to Book	3.08
Revenue Per Employee	$2.2M

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UTHR News

UTHRUnited Therapeutics Corp